Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? (Q38029564)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

4

Stefania Pittaluga

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

6

Wyndham H Wilson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1

Kieron Dunleavy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

2

Cliona Grant

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

3

Franziska C Eberle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

Current hematologic malignancy reports

9 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

241-247

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

The biology of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Pathological, Immunological, and Molecular Features of Hodgkin's Disease Associated with HIV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Large B-cell lymphoma with Hodgkin's features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Pathobiology of primary mediastinal B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-012-0130-5

The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

21 January 2018

1 reference

12 December 2020

Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer

1 reference

12 December 2020

Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma)

1 reference

12 December 2020

The interrelationship of Hodgkin's disease and non-Hodgkin's lymphomas--lessons learned from composite and sequential malignancies

1 reference

12 December 2020

Hodgkin's disease in the setting of human immunodeficiency virus infection

1 reference

12 December 2020

Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients

1 reference

12 December 2020

Mediastinal lymphoma of clear cell type is a tumor corresponding to terminal steps of B cell differentiation

1 reference

12 December 2020

Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin

1 reference

12 December 2020

Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma

1 reference

12 December 2020

Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease

1 reference

12 December 2020

Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells

1 reference

12 December 2020

Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study

1 reference

12 December 2020

Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients

1 reference

12 December 2020

CD23 expression in mediastinal large B-cell lymphomas

1 reference

12 December 2020

Sobering realities of surviving Hodgkin lymphoma

1 reference

12 December 2020

Primary mediastinal lymphoma in adults

1 reference

12 December 2020

CD30 expression is common in mediastinal large B-cell lymphoma

1 reference

12 December 2020

10.1007/S11899-012-0130-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

9 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

22833351

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22833351%20AND%20SRC:MED&resulttype=core&format=json